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Abstract
Prior studies demonstrate that adenosine, acting at one or more
of its receptors, mediates the anti-inflammatory effects of
methotrexate in animal models of both acute and chronic
inflammation. Both adenosine A2A and A3 receptors contribute
to the anti-inflammatory effects of methotrexate treatment in the
air pouch model of inflammation, and the regulation of
inflammation by these two receptors differs at the cellular level.
Because different factors may regulate inflammation at different
sites we examined the effect of low-dose weekly methotrexate
treatment (0.75 mg/kg/week) in a model of acute peritoneal
inflammation in adenosine A2A receptor knockout mice and A3
receptor knockout mice and their wild-type littermates.
Following intraperitoneal injection of thioglycollate there was no
significant difference in the number or type of leukocytes, tumor
necrosis factor alpha (TNF-α) and IL-10 levels that accumulated
in the thioglycollate-induced peritoneal exudates in adenosine
A2A knockout mice or wild-type control mice. In contrast, there
were more leukocytes, TNF-α and IL-10 in the exudates of the
adenosine A3  receptor-deficient mice. Low-dose, weekly
methotrexate treatment increased the adenosine concentration
in the peritoneal exudates of all mice studied, and reduced the
leukocyte accumulation in the wild-type mice and A3 receptor
knockout mice but not in the A2A receptor knockout mice.
Methotrexate reduced exudate levels of TNF-α in the wild-type
mice and A3 receptor knockout mice but not the A2A receptor
knockout mice. More strikingly, IL-10, a critical regulator of
peritoneal inflammation, was increased in the methotrexate-
treated wild-type mice and A3 knockout mice but decreased in
the A2A  knockout mice. Dexamethasone, an agent that
suppresses inflammation by a different mechanism, was similarly
effective in wild-type mice, A2A mice and A3 knockout mice.
These findings provide further evidence that adenosine is a
potent regulator of inflammation that mediates the anti-
inflammatory effects of methotrexate. Moreover, these data
provide strong evidence that the anti-inflammatory effects of
methotrexate and adenosine are mediated by different receptors
in different inflammatory loci, an observation that may explain
why inflammatory diseases of some organs but not of other
organs respond to methotrexate therapy.
Introduction
Low-dose weekly methotrexate has become the mainstay
treatment of rheumatoid arthritis and psoriasis, and it is the
gold standard by which other systemic medications are meas-
ured in both disorders [1,2]. Methotrexate has been used to
treat other inflammatory diseases including ankylosing spond-
ylitis, multiple sclerosis and inflammatory bowel disease, but
its efficacy in the therapy of these conditions is far less impres-
sive [3-7].
An increasing body of evidence indicates that adenosine
mediates, at least in part, the anti-inflammatory effects of meth-
otrexate [8-13]. All known adenosine cell surface receptors
(A1, A2A, A2B and A3) contribute to the modulation of inflamma-
tion, as demonstrated by many in vitro and in vivo pharmaco-
logic studies (reviewed in [14,15]). We have previously
demonstrated pharmacologically, using nonselective antago-
nists, that the anti-inflammatory effect of methotrexate is medi-
ated by more than one subtype of adenosine receptor in the
adjuvant arthritis model in the rat [16], and, using mice ren-
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dered deficient in A2A or A3 adenosine receptors, we found
that both receptor subtypes are critical for the anti-inflamma-
tory effects of methotrexate in the murine air pouch model of
inflammation [17]. Since inflammation at different loci may be
regulated by different cellular mechanisms, we determined
whether the A2A and A3 receptors played similar roles in regu-
lating inflammation in the peritoneum.
We examined the pharmacologic mechanism by which meth-
otrexate diminishes inflammation in the thioglycollate-induced
peritoneal inflammation model of acute inflammation in the
mouse. We report here that, similar to the air pouch, meth-
otrexate treatment increases peritoneal exudate adenosine
concentrations in wild-type mice, A2A receptor knockout mice
and A3 receptor knockout mice but, in contrast to the air pouch
model, diminishes leukocyte accumulation only in the perito-
neal exudates of A3 receptor knockout and wild-type mice, not
of A2A knockout mice. Similarly, methotrexate decreased exu-
date tumor necrosis factor alpha (TNF-α) levels and increased
IL-10 levels in wild-type mice and A3 knockout mice, but only
marginally decreased TNF-α levels and significantly
decreased IL-10 levels in A2A knockout mice.
Materials and methods
Materials
Thioglycollate medium (FTG) was obtained from Sigma Chem-
ical Co. (St Louis, MO, USA). Methotrexate was purchased
from Immunex (San Juan, PR, USA). All other materials were
the highest quality that could be obtained.
Animals
Mice with a targeted disruption of the gene for the adenosine
A2A and A3 receptor have been described in detail elsewhere
[18,19]. The mice used in these experiments were derived
from four original heterozygous breeding pairs for each mouse
strain. Mice described as wild type were specific for the
related receptor knockout mice, since their background was
different. Confirmation of mouse genotype was performed by
PCR as previously described [17]. Mice were housed in the
New York University animal facility, fed regular mouse chow
and given access to drinking water ad libitum. All procedures
described in the following were reviewed and approved by the
Institutional Animal Care and Use Committee of New York Uni-
versity Medical Center and were carried out under the super-
vision of the facility veterinary staff.
Peritoneal inflammation
Animals were given weekly intraperitoneal injections of either
methotrexate (0.75 mg/kg, freshly reconstituted lyophilized
powder) or vehicle (0.9% saline) for 4 weeks and the experi-
ments were carried out within 3 days of the final dose of meth-
otrexate. Dexamethasone (1.5 mg/kg) was administered by
intraperitoneal injection 1 hour prior to induction of inflamma-
tion in the peritoneum. Thioglycollate peritonitis was induced
by intraperitoneal injection of 0.5 ml sterile solution of thiogly-
collate medium (10% w/v in PBS) [20]. After 4 hours the ani-
mals were sacrificed by CO2 narcosis and their peritoneal
cavities were lavaged with 3 ml cold PBS. The peritoneal area
was massaged before withdrawing the lavage fluid. Exudates
were maintained at 4°C until aliquots were diluted 1:1 with
methylene blue (0.01% w/v in PBS) and cells were counted in
a standard hemocytometer chamber. The concentration of
adenosine and TNF-α in inflammatory exudates was quantified
by HPLC and ELISA, respectively [17]. The IL-10 concentra-
tion in cell-free inflammatory exudates was quantified by ELISA
(R&D Systems, Minneapolis, MN, USA) following the manufac-
turer's instructions.
Statistical analysis
All statistical analyses were performed by SigmaStat software
(SPSS, Inc., Chicago, IL, USA). Differences between groups
were analyzed by one-way analysis of variance.
Results
Since previous studies carried out in our laboratory showed
that adenosine receptors play a pivotal role in the formation of
the granulation tissue lining the air pouch [21], in a manner
that might alter the inflammatory response, we sought to fur-
ther evaluate the role of adenosine receptors in methotrexate-
mediated suppression of inflammation in tissue that had not
previously undergone injury or disruption. We therefore deter-
mined whether methotrexate inhibits acute leukocyte accumu-
lation in thioglycollate-induced peritoneal inflammation in wild-
type mice, adenosine A2A receptor knockout mice and adeno-
sine A3 receptor knockout mice. Similar numbers of leukocytes
accumulated in peritoneal inflammatory exudates of A2A knock-
out mice and their corresponding wild-type controls (Table 1).
In contrast, there was a significant increase (20%) in the
number of leukocytes that accumulated in peritoneal exudates
of A3 knockout mice as compared with the wild-type controls
(Table 1).
Treatment with methotrexate increased the exudate adenosine
concentration in wild-type mice, A2A knockout mice and A3
Table 1
Leukocyte accumulation in inflammatory exudates
Mouse group Peritoneal exudate (× 106cells ± 
SEM)
A2A wild type 9.3 ± 0.6 (n = 14)
A2A knockout 9.2 ± 0.8 (n = 14)
A3 wild type 10.6 ± 0.5 (n = 19)
A3 knockout 12.5 ± 0.4* (n = 23)
Inflammatory exudates were induced in the peritoneum of knockout 
and wild-type mice, as described. After 4 hours the exudates were 
collected and the leukocytes quantitated. The wild-type control mice 
were derived from the same heterozygous breeding pairs and were 
matched for age and sex. There was no difference in the number of 
leukocytes accumulating in the exudates of male vs female mice in 
either the knockout mice or wild-type mice. *P < 0.005 vs A3 wild-
type mice, Student's t test.Available online http://arthritis-research.com/content/8/2/R53
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knockout mice (Table 2) and reduced the leukocyte accumu-
lation in A2A wild-type mice by 30 ± 5% (P < 0.01 vs control,
n = 7; Figure 1a), but reduced the leukocyte accumulation in
the A2A knockout mice by only 7 ± 5% (P = not significant vs
wild-type control, n = 6; Figure 1a). In contrast to the A2A
knockout mice, methotrexate was no less effective as an anti-
inflammatory agent in A3 receptor knockout mice (23 ± 5%
inhibition, P < 0.001 vs A3 knockout control, n = 12; Figure
1b) than in A3 wild-type mice (22 ± 5% inhibition, P < 0.001
vs A3 wild-type control, n = 10; Figure 1b).
To determine whether the diminished anti-inflammatory effect
of methotrexate in the A2A knockout mice was specific, we
tested the effect of the potent steroidal anti-inflammatory
agent dexamethasone in this model. Dexamethasone dimin-
ished leukocyte accumulation similarly in A2A wild-type mice,
A2A knockout mice, A3 wild-type mice and A3 knockout mice
(39 ± 9%, 38 ± 13%, 35 ± 4% and 36 ± 4% inhibition, P <
0.005, P < 0.05, P < 0.001 and P < 0.001 vs control, n = 4,
n = 3, n = 9 and n = 9, respectively; Figure 1). Under the con-
ditions studied there was no difference in the type of white
cells that accumulated in the peritoneal cavities of either
treated or untreated wild-type mice or knockout mice (>90%
polymorphonuclear leukocytes).
In general, TNF-α accumulation in peritoneal exudates was
much lower than previously reported in other models of inflam-
mation, including carrageenan-induced inflammation in the air
pouch and zymosan-induced peritoneal inflammation [17,22].
Similar to leukocyte accumulation, we found comparable lev-
els of the proinflammatory cytokine TNF-α in peritoneal exu-
dates of wild-type mice and A2A  knockout mice, but
significantly increased accumulation of TNF-α in peritoneal
exudates of A3 knockout mice (Table 3). Methotrexate never-
theless inhibited TNF-α accumulation in peritoneal exudates of
wild-type mice and A3 knockout mice more markedly than leu-
kocyte accumulation (by 67% and 59%, respectively), and had
a modest effect on TNF-α accumulation in peritoneal exudates
of A2A knockout mice (Table 3). These findings are consistent
with the prior observation that both A2A and A3 receptors mod-
ulate TNF-α production [23].
The cytokine IL-10, released by resident peritoneal macro-
phages, plays a regulatory anti-inflammatory role in the recruit-
ment of leukocytes in murine models of peritoneal
inflammation [22,24]. Since adenosine receptor activation
modulates the release of IL-10 by different inflammatory cells
[25-27] and methotrexate-treated rheumatoid arthritis patients
have shown increased serum levels of this cytokine [28,29],
we determined whether constitutively or methotrexate-modi-
fied IL-10 accumulation in the inflammatory exudate was
altered in adenosine receptor-deficient mice. We found that,
similar to the leukocyte infiltration and the TNF-α concentra-
tion, A3 knockout mice had significantly higher IL-10 levels in
their peritoneal inflammatory exudates when compared with
wild-type mice and A2A knockout mice (Table 4). As expected,
treatment with methotrexate stimulated IL-10 accumulation in
the exudate by 56% in wild-type mice, but significantly
decreased IL-10 levels in exudates of A2A-deficient mice.
Although methotrexate increased IL-10 levels in the exudates
of methotrexate-treated A3 knockout mice, this increase did
not achieve statistical significance. Due to the high variability
in the IL-10 levels we found in our experiments, it would
Figure 1
Effect of methotrexate and dexamethasone treatment on leukocyte  accumulation in peritoneal exudates of mice Effect of methotrexate and dexamethasone treatment on leukocyte 
accumulation in peritoneal exudates of mice. (a) A2A wild-type mice and 
A2A receptor knockout mice or (b) A3 wild-type mice and A3 receptor 
knockout mice either were treated with weekly injections of methotrex-
ate (0.75 mg/kg) or saline control for 4 weeks prior to induction of 
inflammation or were treated with a single intraperitoneal injection of 
dexamethasone (1.5 mg/kg) or saline 1 hour before induction of inflam-
mation and subsequent collection of inflammatory exudates, as 
described. Results are presented as the mean (± SEM) million cells per 
exudate. **P < 0.001 vs wild-type control mice, ++P < 0.001 vs knock-
out control mice, +P < 0.05 vs knockout control mice, all one-way anal-
ysis of variance (Bonferroni t test).Arthritis Research & Therapy    Vol 8 No 2    Montesinos et al.
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require between 30 and 60 mice per group to achieve statis-
tical significance.
These results provide evidence that the anti-inflammatory
effects of methotrexate (and adenosine) are mediated by dif-
ferent receptors in different loci. Specifically, in contrast to our
previously published observation that both A2A and A3 recep-
tors are required for the anti-inflammatory effects in the air
pouch model of inflammation, only the A2A receptor is required
to suppress inflammation in the peritoneal space.
Discussion
The purine nucleoside adenosine is a ubiquitous autacoid
present in all tissues and body fluids. Under basal conditions,
the extracellular adenosine concentration is rather constant
(30–300 nM), but its concentration can increase dramatically
to 10 µM or even higher, as a result of ATP catabolism, when
there is an imbalance between energy use and energy supply,
such as in oxygen depletion, or when there is cell necrosis as
a consequence of mechanical or inflammatory injury. Adenos-
ine acts via four distinct adenosine receptor subtypes – the
adenosine A1, A2A, A2B, and A3 receptors – that are all mem-
bers of the large family of seven-transmembrane spanning,
heterotrimeric G protein-associated receptors, coupling to
classical second messenger pathways such as modulation of
cAMP production or the phospholipase C pathway. In addi-
tion, they couple to mitogen-activated protein kinases, which
could give them a role in cell growth, survival, death and differ-
entiation (reviewed in [30]).
Adenosine is a potent endogenous anti-inflammatory agent,
and all four adenosine receptor subtypes participate in this
effect (reviewed in [14]). All cell subtypes involved in the
inflammatory process differentially express functional adenos-
ine receptors. It is well documented that microvascular
endothelial cells, major players conducting the movement of
leukocytes between tissue compartments, express adenosine
A2A and A2B receptors [31,32]. Pharmacological and molecu-
lar approaches have shown that neutrophils, monocytes and
macrophages express all four adenosine receptor subtypes.
Although adenosine A1 receptor activation has been associ-
ated with proinflammatory properties in inflammatory cell types
[33-35], the anti-inflammatory effect of selective A1 agonists
acting in the central nervous system has been demonstrated
in vivo [36-38]. Adenosine A2A receptor activation inhibits
neutrophil and monocyte oxidative burst, degranulation and
release of cytokines and chemokines [39-41]. Activation of
A2B receptors selectively inhibits collagenase mRNA accumu-
lation in synovial fibroblasts and mediates neutrophil-stimu-
lated intestinal epithelial leakiness [42,43]. Adenosine A3
receptors have also been described as anti-inflammatory in
human blood leukocytes and in murine models of inflammation
[19,44-46].
The results of these reported studies confirm the anti-inflam-
matory effects of adenosine acting at A3 receptors because
animals deficient in this receptor show an exacerbated
response to the inflammatory insult. Moreover, we found that
more polymorphonuclear leukocytes accumulate in the perito-
neal exudates of A3 knockout mice in comparison with their
wild-type littermates, consistent with the hypothesis that this
receptor plays a greater role as an endogenous regulator of
inflammation. Our data are in agreement with prior reports
showing that adenosine A3 receptor agonists suppress the
expression and production of macrophage inflammatory pro-
tein 1α, a chemokine that enhances neutrophil recruitment into
inflammatory sites [45], and suppress the production of TNF-
α by lipopolysaccharide-stimulated macrophages [19]. Ade-
nosine A3 receptor agonists thus ameliorate joint inflammation
in several murine models of arthritis [45,46].
Monocytes and macrophages synthesize and release into their
environment a variety of cytokines and other proteins that play
a central role in the development of acute and chronic inflam-
mation. It has been firmly established that adenosine modu-
lates the production of inflammatory cytokines, including TNF-
α, IL-10, and IL-12 [23,25-27,47]. In addition to the regulatory
effect of adenosine in cytokine secretion, we have further
established that Th1 proinflammatory cytokine IL-1 and TNF-α
treatment increases message and protein expression of A2A
and A2B receptors by both microvascular endothelial cells and
THP-1 monocytoid cells. IFN-γ treatment also increased the
expression of A2B receptors, but decreased the expression of
A2A receptors [25,32,48]. It is therefore probably at inflamed
sites, where proinflammatory cytokines such as IL-1 and TNF-
α are abundantly secreted, mostly by monocytes/macro-
Table 2
Adenosine concentration in peritoneal exudates
Wild-type mice (nM ± SEM) A2A knockout mice (nM ± SEM) A3 knockout mice (nM ± SEM)
Control 118 ± 6 (n = 19) 110 ± 6 (n = 14) 133 ± 6 (n = 12)
Methotrexate (0.75 mg/kg/week) 178 ± 12* (n = 15) 162 ± 7** (n = 7) 214 ± 10† (n = 9)
Wild-type mice, A2A receptor knockout mice or A3 receptor knockout mice were treated with either weekly injections of methotrexate (0.75 mg/kg) 
or saline control for 4 weeks prior to induction of inflammation. Inflammatory exudates were induced in the peritoneum of mice, as described. After 
4 hours the exudates were collected and the adenosine levels quantitated. Wild-type data are a combination from both mouse strains. *P < 
0.0001 vs wild-type control mice, Student's t test; **P < 0.0001 vs A2A knockout control mice, Student's t test; † P < 0.0001 vs A3 knockout 
control mice, Student's t test.Available online http://arthritis-research.com/content/8/2/R53
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phages, that the subsequent upregulation of A2A and A2B
receptors on endothelial cells and other inflammatory cells
along with endogenous adenosine release constitutes a feed-
back loop to suppress further inflammation. The demonstra-
tion that adenosine receptors expressed in microvascular
endothelial cells are modified during inflammation suggests an
important role for these receptors in the increased angiogen-
esis and vascular permeability that characterize both acute
and chronic inflammatory responses. Moreover, in previous
studies, activation of both A2A and A2B receptors on either
endothelial cells or macrophages has been reported to
enhance the expression of vascular endothelial growth factor
and to promote angiogenesis [21,49-51].
Methotrexate is an effective disease-modifying drug widely
used in low doses at weekly intervals for the control of rheu-
matoid arthritis and psoriasis with a relatively safe profile com-
pared with other therapies [1,2]. Since folate administration
prevents many of the toxicities of methotrexate without affect-
ing the therapeutic effects [52], there is little support for the
hypothesis that inhibition of folate-dependent pathways (for
example, cellular proliferation) is responsible for the therapeu-
tic effects of the agent. Following administration, methotrexate
is taken up by cells and undergoes polyglutamation, resulting
in the intracellular accumulation of the long-lived polygluta-
mates of methotrexate. These metabolites, in addition to inhib-
iting folate metabolism, directly inhibit 5-aminoimidazole-4-
carboxamide ribonucleotide transformylase, resulting in an
intracellular accumulation of 5-aminoimidazole-4-carboxamide
ribonucleotide, which is an intermediate metabolite in the de-
novo pathway of purine synthesis, and has been associated
with increases in extracellular adenosine [9,13,53].
There is now increasing evidence that accumulation of adeno-
sine at sites of inflammation plays a pivotal role in the anti-
inflammatory effect of methotrexate. In vitro studies showed
that methotrexate produces adenosine release by human
fibroblasts and endothelial cells [53], and in vivo studies
showed that methotrexate is ineffective in the presence of
antagonists of adenosine or adenosine deaminase (the
enzyme responsible for the deamination of adenosine to inos-
ine) in animal models of acute and chronic inflammation [8].
Moreover, adenosine receptor antagonists and deletion of
adenosine receptors eliminates the anti-inflammatory
response to methotrexate in animal models of acute and
chronic inflammation and patients with rheumatoid arthritis
[13,16,54].
Although the contribution of adenosine to the mechanism of
action of methotrexate is well accepted, it is still unclear which
adenosine receptors participate in the effect of methotrexate.
Results of early studies, using pharmacological tools, sug-
gested that the adenosine A2A receptor was the main receptor
subtype involved in suppressing inflammation [8]. In the model
of adjuvant arthritis in rats, however, we found that only nonse-
lective adenosine receptor antagonists could block the pro-
tective effect of methotrexate whereas selective antagonists of
individual adenosine receptors did not alter the response to
methotrexate [16], consistent with involvement of multiple
adenosine receptors. Using knockout animals we observed
that both A2A and A3 adenosine receptors are involved in meth-
otrexate-mediated suppression of air pouch inflammation [17]
but, as reported here, only A2A receptors are involved in meth-
otrexate-mediated suppression of peritoneal inflammation.
Methotrexate exerted similar anti-inflammatory effects in wild-
Table 3
Tumor necrosis factor alpha concentration in peritoneal exudates
Wild-type mice (pg/ml ± SEM) A2A knockout mice (pg/ml ± SEM) A3 knockout mice (pg/ml ± SEM)
Control 42 ± 7 (n = 14) 36 ± 8 (n = 10) 75 ± 18* (n = 6)
Methotrexate (0.75 mg/kg/week) 14 ± 4** (n = 15) 25 ± 7 (n = 9) 31 ± 11† (n = 8)
Wild-type mice, A2A receptor knockout mice or A3 receptor knockout mice were treated with either weekly injections of methotrexate (0.75 mg/kg) 
or saline control for 4 weeks prior to induction of inflammation. Inflammatory exudates were induced in the peritoneum of mice, as described. After 
4 hours the exudates were collected, centrifuged at 100 × g and frozen. Tumor necrosis factor alpha levels were later quantitated by ELISA. Wild-
type data are a combination from both mouse strains. **P < 0.001 vs wild-type control mice, Student's t test; *P < 0.05 vs wild-type control mice, 
Student's t test; †P < 0.05 vs A3 knockout control mice, Student's t test.
Table 4
IL-10 concentration in peritoneal exudates
Wild-type mice (pg/ml ± SEM) A2A knockout mice (pg/ml ± SEM) A3 knockout mice (pg/ml ± SEM)
Control 62 ± 7 (n = 24) 73 ± 9 (n = 12) 115 ± 14** (n = 15)
Methotrexate (0.75 mg/kg/week) 97 ± 18* (n = 12) 41 ± 6† (n = 7) 150 ± 31 (n = 7)
Wild-type mice, A2A receptor knockout mice or A3 receptor knockout mice were treated with either weekly injections of methotrexate (0.75 mg/kg) 
or saline control for 4 weeks prior to induction of inflammation. Inflammatory exudates were induced in the peritoneum of mice, as described. After 
4 hours the exudates were collected, centrifuged at 100 × g and frozen. IL-10 levels were later quantitated by ELISA. Wild-type data are a 
combination from both mouse strains. ** P < 0.001 vs wild-type control mice, Student's t test; * P < 0.05 vs wild-type control mice, Student's t 
test; †P < 0.05 vs A2A knockout control mice, Student's t test.Arthritis Research & Therapy    Vol 8 No 2    Montesinos et al.
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type mice and A3 knockout mice, but failed to inhibit leukocyte
and TNF-α accumulation in A2A knockout mice. Moreover,
methotrexate treatment augmented the accumulation of IL-10,
a known anti-inflammatory cytokine, in wild-type mice and A3
knockout mice, but actually decreased IL-10 levels in A2A
knockout mice. We do not have a clear explanation for this
other than to note it is probable that in the MTX-treated A2A
knockout mice there is an imbalance in A1 adenosine receptor
function in the absence of A2A, consistent with the previous
observation of Hasko and colleagues that an A1 adenosine
receptor agonist reduces IL-10 release by lipopolysaccharide-
stimulated RAW macrophages [27]. IL-10 is therefore, as pre-
viously reported, a critical regulator of peritoneal inflammation
that is regulated by A2A adenosine receptors but not by A3
adenosine receptors [24,25].
We infer from these results and previous reports that the
involvement of different adenosine receptor subtypes
depends upon the site of and stimulus for inflammation. We
therefore conclude it is probable that the requirement for acti-
vation of multiple adenosine receptor subtypes in the pharma-
cologic control of chronic inflammation results from the
involvement of different types of inflammatory cells and dis-
ease-specific differences in the inflammatory environment.
Conclusion
The studies reported here provide strong evidence that adeno-
sine mediates the anti-inflammatory effects of methotrexate at
doses relevant to those used to treat inflammatory arthritis.
These results indicate that agents which interact with adenos-
ine A2A receptors directly or promote adenosine release at
inflamed sites may be useful for the treatment of inflammatory
conditions, whereas occupancy of other adenosine receptors
may be involved in suppression of inflammation in a site-spe-
cific fashion.
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